Illumina, Inc. vs Vital Farms Inc — how do they compare? Illumina, Inc. trades at $267.9 (market cap $39.95B), while Vital Farms Inc trades at $9.43 (market cap $405.27M). The key difference: Illumina, Inc. is far larger — about 98.6× Vital Farms Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Vital Farms Inc for 14 Days on average.
| ILMN | VITL | |
|---|---|---|
Market Cap | $39.95B | $405.27M |
Volume | 3,169,503 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $293.69 | $43.68 |
52-Week Low | $91.00 | $8.28 |
Typical Hold Time | 83 Days | 14 Days |
Enterprise Value | $41.31B | $492.28M |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Vital Farms (VITL) trades at $9.45, up 2.27% today, amid a challenging fundamental backdrop. The stock exhibits a bearish technical trend, with recent earnings showing significant pressure on profitability. Revenue for 2025 was $759.44M with a net income of $66.28M, but 2026 projections indicate a sharp decline in net income to near breakeven. Recent news highlights strategic review discussions and institutional investment activity, contributing to volatile price action.
The outlook is mixed; analyst consensus is bullish with a $13.11 price target, but near-term risks from egg pricing pressure and weak profitability metrics pose challenges. Investment opportunity hinges on successful execution of strategic options and margin recovery, while downside risks include sustained industry oversupply and cash flow constraints.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →